title: The impact of timing of EGFR and IGF-1R inhibition for sensitizing head and neck cancer to radiation.
abstract: BACKGROUND
  Targeting the epidermal growth factor receptor (EGFR) improved radiotherapy outcome by 10-15% in head and neck tumors (HNSCC). We tested the therapeutic benefits of co-targeting EGFR and insulin-like growth factor-1 receptor (IGF-1R) to further enhance tumor response to radiation.
  
  
  METHODS
  Mice bearing FaDu tumor xenografts were treated with ganitumab (previously known as AMG479, an anti-IGF-1R antibody), panitumumab (an anti-EGFR antibody), or both in combination with fractionated doses of radiation. Tumor growth delay and tumor cure/recurrence served as end-points.
  
  
  RESULTS
  The best tumor growth delay was achieved when ganitumab and panitumumab were given concurrently with radiation. Tumor cure/recurrence studies showed that combining ganitumab, panitumumab and radiation resulted in significantly higher radiocurability rates than use of either of the agents given with radiation.
  
  
  CONCLUSIONS
  These findings provide the rationale for clinical testing of the combination of ganitumab and panitumumab for the treatment of HNSCC.
authors: Department of Experimental Radiation Oncology, The University of Texas M.D. Anderson Cancer Center, Unit 66, 1515 Holcombe Blvd., Houston, TX 77030, USA.
authors: Fumihiko
authors: F
authors: Matsumoto
authors: David N
authors: DN
authors: Valdecanas
authors: Kathryn A
authors: KA
authors: Mason
authors: Luka
authors: L
authors: Milas
authors: K Kian
authors: KK
authors: Ang
authors: Uma
authors: U
authors: Raju
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000378:metabolism / Q000532:radiotherapy*; D045744:Cell Line, Tumor; D019583:Dose Fractionation, Radiation; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D006258:Head and Neck Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000532:radiotherapy*; D006801:Humans; D051379:Mice; D000077544:Panitumumab; D011836:Radiation Tolerance; D017526:Receptor, IGF Type 1 / Q000037:antagonists & inhibitors*; D014183:Transplantation, Heterologous
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000077544:Panitumumab; C545764:ganitumab; D066246:ErbB Receptors; D017526:Receptor, IGF Type 1